Topics

Meningioma | Treatment | Targeted Therapy

Home > Publications > Topics > Meningioma > Treatment > Targeted Therapy

Limon D, Amiel A, Even Haim S, Gordon N, Tschernichovsky R, Stemmer S, Gal O, Laviv Y, Kanner A, Siegal T, Yust-Katz S.
A phase II, open-label, single-arm trial of pembrolizumab for recurrent meningioma and solitary fibrous tumor.
Neurooncol Adv. 2024 Sep 16;6(1):vdae154. doi: 10.1093/noajnl/vdae154. PMID: 39429970. Interventional study. ˍ

Hajikarimloo B, Hasanzade A, Sabbagh Alvani M, Habibi MA.
Application of bevacizumab in the management of meningiomas: a systematic review and meta-analysis.
Neurosurg Rev. 2024 Sep 27;47(1):692. doi: 10.1007/s10143-024-02889-w. PMID: 39327340. Review˰ ˍ

Bosio A, Cerretti G, Padovan M, Del Bianco P, Polano M, Mandruzzato S, Indraccolo S, Manara R, Librizzi G, Caccese M, Corrà M, Maccari M, Lonardi S, De Salvo GL, Lombardi G.
Regorafenib versus local standard of care in patients with grade 2-3 meningioma no longer eligible for loco-regional treatments: a phase II randomized controlled trial (the MIRAGE study).
Trials. 2025 Aug 4;26(1):268. doi: 10.1186/s13063-025-08997-2. PMID: 40759981. Interventional study protocol. ˍ AI Overview